Company intelligence / Profile preview
Biocidium Biopharmaceuticals
Chatsworth, California, United Statesbiocidium.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Biocidium has multiple candidates in preclinical and early clinical stages. Their antibiotics have shown 99.99%+ efficacy against 90%+ of bacteria listed by the CDC, FDA, and ESKAPE Program as drug-resistant or multi-drug resistant. Their antifungals have demonstrated efficacy against 100% of fungal infections listed by both the CDC and FDA as drug-resistant and multi-drug resistant fungi.
- Therapeutic areas
- OncologyDermatologyInfectious Diseases
- Modalities
- Small moleculeschemical drugs
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
Beyond the preview
Go deeper on Biocidium Biopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biocidium Biopharmaceuticals.